Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, today announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing vi
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price of $14.83 USD, the closing trading price on August 31,
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Results Earnings Conference Call August 11, 2020, 04:30 PM ET Company Participants Glenn Schulman - SVP, Corporate Communications and IR Peter Greenleaf - CEO and Director Neil Solomons - Chief Medical Officer Max Colao - Chief Commercial Officer Joe Miller - Chief Financial Officer...